AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06274931 — intervention group
Intervention type: PROCEDURE
Intervention: Bronchoscopy
Description: Through a bronchoscopic examination performed at the time of admission for diagnostic purposes, an alveolar bronchial lavage was performed for the analysis of the lung microbiome.
Study NCT04804761 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Needle insertion on bilateral LI4 HeGu and PC6 NeiGuan and ipsilateral ST6 JiaChe and ST7 XiaGuan (as shown in Table 1), using disposable sterile acupuncture needles (length 25 mm, diameter 0.25 mm; Seirin Corporation, Shizuoka, Japan)
Study NCT04804761 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Electroacupuncture
Description: Needle insertion on bilateral LI4 HeGu and PC6 NeiGuan and ipsilateral ST6 JiaChe and ST7 XiaGuan (as shown in Table 1), using disposable sterile acupuncture needles (length 25 mm, diameter 0.25 mm; Seirin Corporation, Shizuoka, Japan)
Study NCT05564481 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diabetes education and parent coaching support
Description: Intervention sessions will include parent/child discussion about barriers to CGM use, review of CGM data, problem solving, and working as a team.
Study NCT05564481 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diabetes education and parent coaching support
Description: Intervention sessions will include parent/child discussion about barriers to CGM use, review of CGM data, problem solving, and working as a team.
Study NCT05493293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-921352
Description: Tablets for oral administration
Study NCT04799925 — intervention group
Intervention type: DRUG
Intervention: Febuxostat
Description: uric acid lowering agent. dose: 80 mg once daily. duration: for 6 months
Study NCT06011434 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mammography Screening Conversation Aid
Description: Web-based, Decide Together conversation aid designed to be used by PCP and participant for shared decision making and to provide information on the benefits and harms of mammography screening as well as educational talking points.
Study NCT05245383 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ten products (S01~S10) and two blank (BK1, BK2)
Description: S01 Functional Peptides Recovering Essence EX S02 Advanced Revitalizing Eye Cream S03 Advanced Revitalizing Lotion S04 NB-1 Anti-Sensitive Repair Activator S05 NB-1 Anti-Sensitive Repair Toning Extract S06 Ginseng Vitality Serum S07 Ginseng Revitalizing Age-defense Essence Cream S08 Ginseng Age-defense Eye Cream S09 Revital Energy Balance Gel S10 Revital Energy Tightening Body Lotion BK1 Water BK2 Blank ten products and two blank, 24 hours single application patch test on the back.
Study NCT05611112 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy
Description: Problem Solving Therapy is a well-established evidence-based therapy form that is highly effective in patients with mental health issues. Initially, the patient makes a problem list and for each problem, possible solutions will be outlined. Considering pros and cons for each solution, the patient is asked to choose the one considered most appropriate. The patient is encouraged to put this solution into action and a follow-up consultation is planned.
Study NCT05022537 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: retrograde nephrostomy
Description: this will consist of one visit to a urologist for retrograde nephrostomy placement using a Retroperc device with lithotomy performed in the same visit and follow up at 4 weeks and 6 months.
Study NCT05022537 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: antegrade nephrostomy
Description: this will consist of two visits, first to the interventional radiologist for antegrade nephrostomy placement followed by another visit to the urologist for lithotomy with follow up at 4 weeks and 6 months
Study NCT05849480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Oxaliplatin (130 mg/m2) will be administered IV on Day 1 of each cycle, every 21 days (up to 6 cycles).
Study NCT05849480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Capecitabine (750 mg/m2 every 12 hours) will be administered orally with an intermittent schedule: 2 weeks on, 1 week off, of each cycle, every 21 days (up to 6 cycles).
Study NCT05849480 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Keytruda
Description: Pembrolizumab (200 mg) will be given IV on Day 8 of each cycle every 21 days (up to 6 cycles).
Study NCT05849480 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDX-1140
Description: CDX-1140 (0.36-1.5 mg/kg; per assigned dose level) will be given IV on Day 8 of each cycle every 21 days (up to 6 cycles).
Study NCT05679674 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Body Radiation (SABR)
Description: 50 Gy in 5 fractions, once per day for 5 days
Study NCT05679674 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields (TTF)
Description: Participant will use the system for at least 18 hours per day starting on the first day of SABR until abdominal disease progression. Short treatment breaks are permitted for personal needs (such as to take a shower) and during radiation therapy. An additional treatment break is permitted for up to 48 hours every 21 days.
Study NCT05330988 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anodal transcranial direct current stimulation (a-tDCS)
Description: The 1x1 platform is the most state-of-the-art, customizable, and reliable platform for pad-based Transcranial Electrical Stimulation.
Study NCT05330988 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: The 1x1 platform is the most state-of-the-art, customizable, and reliable platform for pad-based Transcranial Electrical Stimulation.
Study NCT04974333 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile health application on phone
Description: Patients will use a mobile app on their smart phones
Study NCT04356677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg/mL Virazole
Description: 50 mg/mL Virazole aerosolized and administered over 1 hour twice a day for up to 6 days.
Study NCT04356677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg/mL Virazole
Description: 100 mg/mL Virazole aerosolized and administered over 30 minutes twice a day for up to 6 days.
Study NCT05105347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab plus different doses of oral glucocorticosteroid
Description: A loading dose of 80mg adalimumab will be given subcutaneously and then change to 40mg adalimumab every two weeks. Medium dose oral glucocorticosteroid (30mg/d prednisone or equivalent) will be given to the experimental dose group and high dose oral glucocorticosteroid (60mg/d prednisone or equivalent) will be given to the high dose group.
Study NCT05105347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab plus different doses of oral glucocorticosteroid
Description: A loading dose of 80mg adalimumab will be given subcutaneously and then change to 40mg adalimumab every two weeks. Medium dose oral glucocorticosteroid (30mg/d prednisone or equivalent) will be given to the experimental dose group and high dose oral glucocorticosteroid (60mg/d prednisone or equivalent) will be given to the high dose group.
Study NCT05444608 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breast milk olfactory stimulation
Description: Before the intervention, 2 ml of breast milk will be dripped into sterile sponge and the sponge will be placed within 3 cm of the newborn's nose.Babies in this group will start to smell their mother's milk 5 minutes before the procedure and will continue to smell for 5 minutes after the procedure.
Study NCT05444608 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: White noise auditory stimulation
Description: Before the intervention, a bluetooth speaker will be placed at the baby's feet. The speaker will be connected to the phone and the sound level will be adjusted to 50 decibels by means of a decibel meter. The baby will be started to listen to white noise 5 minutes before the procedure and will continue to listen for 5 minutes after the procedure.
Study NCT06466720 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neurocognitive testing
Description: The MoCA is a brief tool developed to screen mild cognitive impairment and has been validated in patients aged 55-85 years old. It has been tested and validated in patients with brain metastases, and its acceptability has been tested in the general brain tumour population. The paper version of the MoCA is available in nearly 100 languages. The online version is available currently in 5 languages.
Study NCT06466720 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quality of Life questionnaire
Description: The EORTC-QLQ-C30 is a quality-of-life questionnaire that was developed by the European Organisation for Research and Treatment of Cancer (EORTC) for use in clinical trials. It is a 30-item questionnaire that incorporates the following five scales: physical, role, cognitive, emotional and social. It has also been validated and is available in more than 100 languages. The EORTC-QLQ-BN20 is a questionnaire that was developed for use specifically with patients that have brain cancer. The BN20 is a 20-item questionnaire and addresses four different scales (multi-item): future uncertainty, visual disorder, motor dysfunction and communication deficit. There are seven items that assess physical symptoms: headaches, seizures, drowsiness, hair loss, itchy skin, weakness of legs and bladder control. The questionnaire has been validated in over 15 languages. The two questionnaires are meant to complement each other when used in patients with brain cancer.
Study NCT06466720 — intervention group
Intervention type: RADIATION
Intervention: Stereotactic radiosurgery
Description: This is a Standard of Care treatment for all the patients that will be recruited in both cohorts. Stereotactic radiosurgery will be delivered to one or more sites and in the prospective cohort can be delivered more than once.
Study NCT04672811 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study App and Apple Watch
Description: Study App and Apple Watch
Study NCT05846230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1291583
Description: Tablet
Study NCT05846230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BI 1291583
Description: Tablet
Study NCT06316635 — intervention group
Intervention type: PROCEDURE
Intervention: ventilation tube insertion
Description: a paracentesis will be done to tympanic membrane. Glu will be aspirated and trapped.
Study NCT06387758 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low systemic strength training
Description: Low systemic strength training. Youth will complete exercise training for 45 minutes. Eight specific exercises will be performed to target all major muscle groups: calf raises, handgrip, squats, seated row, chest press, plank, low bac extension, and crunches (Table 1). Each exercise involves contractions with moderate load but with an extended duration of up to five minutes.16,17 During each exercise session, youth will have a 5-minute warm up, 5-minute cool down, and be allowed to take rest breaks as needed (minimum 30 seconds). Youth will initially progress by decreasing the number of rest periods and then increasing load. Youth will be provided a 2 lb medicine ball, resistance weight bands, Thera Putty, and a Yoga mat for home exercises. Youth will keep this home exercise equipment.
Study NCT06387758 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate systemic exercise
Description: Youth assigned to the moderate systemic exercise load group will perform whole-body aerobic exercise at 40-59% of heart rate reserve (HRR) for 45 minutes.76,111 Youth will complete moderate systemic aerobic exercise by walking at a brisk pace and swinging their arms as they walk. Exercise personnel will supervise a 5-minute warm up and 5-minute cool down via videoconferencing and remain on the phone with youth at all times during the walking exercise session. Youth will exercise until the prescribed duration is achieved or until fatigue at which point they will either reduce the intensity or stop until they recover. All training intensities will be based around HRR so it is individualized (not exceeding 59% of HRR). Youth unable to meet the initial training requirements will be slowly progressed over the 8 weeks.
Study NCT05609396 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviorally enhanced reminder letter
Description: Behavioral interventions to increase FIT-based colorectal cancer screening uptake
Study NCT05861414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EWM-T
Description: This paradigm was adapted from the n-back program described by Jaeggi et al. (2009) and comprised an affective dual n-back task consisting of a series of trials, each of which simultaneously presented a face (for 500 ms) on a 4 × 4 grid on a monitor. Intermediate interval 2500ms, during which, Participants press a button to determine if the current face or position is consistent with the first n. If the position is the same, press F; if the face is the same, press J; if the face and position are not the same, do not react.~The faces used in this training were selected from the Chinese Facial Emotional Picture System (CFAPS), and 12 faces (six male and six female) with fear, anger, disgust, and sadness were selected as n-back experimental materials.
Study NCT04912843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NR082 injection
Description: Intravitreal injection（IVT）
Study NCT04912843 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Injection
Description: Sham Intravitreal Injection
Study NCT05970250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body vibration group
Description: Whole body vibration apparatus (model Power plate -my5tm, made in United States) with frequency 30 - 40 Hz was used for the whole body vibration program by reciprocating vertical displacements on the left and right side of a fulcrum.
Study NCT05970250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight bearing exercises
Description: Electronic treadmill Kettler- marathon model No 7899-800, made in Germany (as form of weight bearing exercises), which was adjusted to the subject's comfortable walking speed. Generally, during the treadmill training, its speed and inclination are electronically adjusted, and it is also provided with a control panel to display the exercise parameters. It allows for the comfortable running without joint or back pains through a perfect combination between aluminium-pertinax running deck, shock absorbers and overall shock-damping design.
Study NCT05970250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D supplements and calcium
Description: vitamin D supplements and calcium
Study NCT05970250 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: vitamin D supplements and calcium
Description: vitamin D supplements and calcium
Study NCT05179070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: the first is the rapid up-titration group, which will get carvedilol up-titration every day, 3.125mg twice daily on the first day, 6.125mg twice daily on the second day, 12.5mg twice daily on the third day and 25mg twice daily on the fourth day consecutively. And the second group will have carvedilol titration according to established guidelines on Heart Failure, start 3.125mg twice daily, and up titrated every 2 weeks
Study NCT05179070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: the first is the rapid up-titration group, which will get carvedilol up-titration every day, 3.125mg twice daily on the first day, 6.125mg twice daily on the second day, 12.5mg twice daily on the third day and 25mg twice daily on the fourth day consecutively. And the second group will have carvedilol titration according to established guidelines on Heart Failure, start 3.125mg twice daily, and up titrated every 2 weeks
Study NCT06261632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction
Description: The intervention protocol through blood flow restriction in patients with hemophilic arthropathy will include performing squats and knee extension for 5-10 and 10 minutes respectively. In both exercises, 4 series will be performed (30, 15, 15, 15 repetitions) with 30 seconds of rest between series
Study NCT05925231 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Box and Block Test
Description: 3 attempts of each subtest of the Box and Block Test performed according to the Czech Extended Version of Manual for the Box and Block Test
Study NCT05510427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infigratinib
Description: Given by PO
Study NCT05510427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given by (IV) vein
Study NCT05510427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given by (IV) vein
Study NCT05074953 — intervention group
Intervention type: OTHER
Intervention: Exposed to a SARS-CoV-2 infection
Description: The study compared humans exposed to the SARS-CoV-2 infection with a matched group of those not exposed. No Intervention was applied.
Study NCT04796766 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High frequency stimulation (HFS)
Description: Electrical stimuli via circular electrode array. The electrode array serves as cathode placed above the eyebrow. A surface electrode (anode) will be placed on the temple. Electrical stimuli will be applied via a constant current stimulator. The stimulus intensity for the electrophysiological protocol is adjusted to the 10-fold of the detection threshold. A number of 5 electrical pulses (2 ms, 100 Hertz (Hz)), 10 second intervals.
Study NCT04796766 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Low-frequency sinusoidal transcutaneous stimulation (sLFS)
Description: Stimulation of C-nociceptors with constant current stimulator. Electrodes (placed on the proband's forehead. Stimulation by sine wave pulses of 250 ms duration (4 Hz), intensities inducing a pain intensity of 50/100 on a visual analogue scale from 0-100.
Study NCT05780138 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents Taking Action
Description: Educational intervention designed to provide caregivers of children with autism information about autism, and strategies to advocate and support their child's development.
Study NCT06487130 — intervention group
Intervention type: OTHER
Intervention: N/A Observational Registry
Description: Registry participants may select to be contacted for future research and/or embedded clinical trials. Such interventions will require associated ethics review \& approval.
Study NCT04797052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefrontal EEG (VEEGix by NeuroServo)
Description: Prefrontal EEG reading
Study NCT05410639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: online education program
Description: The training we provided was to give exercises and advice to parents according to the age of the baby in order to stimulate the motor and social development of the baby,and then, an improvement in the stress state of the parents by their participation in the care of their baby.The training, which began with the discharge of the baby from the hospital, was in the form of slide presentations and videos.
Study NCT05410639 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no online education program
Description: Parents and their infants in the control group did not receive any online education program
Study NCT05601427 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: aACB
Description: The patient will undergo a pre-operative single-shot, ultrasound-guided ACB performed by an anaesthesiologist skilled in regional anaesthesia techniques. The ACB will be performed in a dedicated block room, immediately prior to administration of a spinal anaesthetic.
Study NCT05601427 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sACB
Description: The patient will undergo an intraoperative single-shot ACB performed by the treating surgeon following placement of the TKA components.
Study NCT04735848 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron-supplement application
Description: The participants will take the corresponding amount of iron-supplement supervised at 8am.
Study NCT04555785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wilate
Description: Wilate ® will be given with platelets in cases of severe bleeding. Wilate ® is a 1:1 balanced mixture of von Willebrand Factor (2'000 IU) and Coagulation factor VIII (2'000 IU) and as such has anti-haemorrhagic potential. It is extracted from plasma, freeze-dried and virus-inactivated.
Study NCT04555785 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Empty placebo will be given with platelets in cases of severe bleeding.
Study NCT05483868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AU-011
Description: Administration of AU-011 intratumorally and intramurally
Study NCT05483868 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AU-011 in Combination with Medical Laser Adminstration
Description: AU-011 Intratumorally and Intramurally
Study NCT05483868 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AU-011 in Combination with Medical Laser Administration
Description: AU-011 Intratumorally
Study NCT06406335 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Health education program
Description: Impact of A Multidimensional Health Education Program on Attention deficit hyperactivity disorder (ADHD)
Study NCT05032144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSA-1002 injection
Description: Intravenous injection
Study NCT05032144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous injection